Investigating the brain's response to inflammation in major depressive disorder
Official title: Neural Response to Inflammatory Challenge in Major Depressive Disorder
Run by Laureate Institute for Brain Research, Inc. · NCT04751331 · Data updated 2026-11-12
This study is testing how people with major depressive disorder react to inflammation compared to healthy individuals to see if it affects their symptoms and brain activity.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 180 (estimated) |
| Sponsor | Laureate Institute for Brain Research, Inc. Academic / other |
| Locations | 1 site (Tulsa, Oklahoma) |
| Status | Recruiting |
| Started | May 15, 2021 |
| Main results expected | April 2026 |
| Study ends | December 2026 |
| Registry record updated | April 21, 2026 |
| Trial ID | NCT04751331 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18-65 with a diagnosis of major depressive disorder and current depressive symptoms.
✕Probably not a fit
Patients with severe medical conditions or those who are pregnant may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study examines how individuals with major depressive disorder (MDD) respond to an inflammatory challenge using lipopolysaccharide (LPS) compared to healthy controls. Participants will be randomly assigned to receive either LPS or a placebo, and their immune responses and neural activity will be measured through various assessments, including MRI scans and symptom questionnaires. The study aims to identify specific immune pathways and neural circuits that differ between MDD patients and healthy individuals, as well as to explore the relationship between inflammation and depressive symptoms.
Why it matters
Potential benefit: If successful, this study could lead to new insights into the biological mechanisms of major depressive disorder and potential new treatment strategies.
How similar studies have gone: While studies on inflammation and depression have been conducted, this specific approach using LPS in a controlled setting is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
Both healthy controls and depressed participants will be required to be in good general health (as evaluated during Visit 1, including EKG) and to be 18-65 years of age. A DSM-V diagnosis of MDD will be made with the MINI International Neuropsychiatric Interview and current symptoms of depression will be measured with the clinician-administered MADRS and the self-report PHQ-9. Depressed participants will be required to have symptoms of depression (i.e. a PHQ-9 score ≥10) and/or a MADRS score of ≥7.
Exclusion Criteria:
General Exclusion Criteria:
* Pregnancy
* A history of fainting during blood draws will be evaluated by the clinical team and may be deemed exclusionary.
Medical Conditions:
* Moderate to severe traumatic brain injury (\>30 min. loss of consciousness or \>24 hours posttraumatic amnesia) or other neurocognitive disorder with evidence of neurological deficits.
* Presence of co-morbid medical conditions not limited to but including cardiovascular (e.g., history of acute coronary event, stroke) and neurological diseases (e.g., Parkinson's disease), as well as pain disorders.
* Presence of co-morbid inflammatory disorders such as rheumatoid arthritis or other autoimmune disorders.
* Presence of an uncontrolled medical condition that is deemed by the investigators to interfere with the proposed study procedures, or to put the study participant at undue risk.
* Presence of chronic infection that may elevate pro-inflammatory cytokines.
* Presence of an acute infectious illness or receipt of a vaccination in the two weeks prior to an experimental session.
Psychiatric Disorders:
* Current severe suicidal ideation or attempt within the past 12 months.
* Psychosis
* Bipolar disorder
* Substance abuse or dependence within the previous 6 months
Contraindications for MRI:
* Cardiac pacemaker, metal fragments in eyes/skin/body (shrapnel), aortic/aneurysm clips, prosthesis, by-pass surgery/coronary artery clips, hearing aid, heart valve replacement, shunt (ventricular or spinal), electrodes, metal plates/pins/screws/wires, or neuro/bio-stimulators (TENS unit), persons who have ever been a professional metal worker/welder, history of eye surgery/eyes washed out because of metal, vision problems uncorrectable with lenses, inability to lie still on one's back for 60 minutes; prior neurosurgery; tattoos or cosmetic makeup with metal dyes, unwillingness to remove body piercings, and pregnancy.
* Claustrophobia that is severe enough to preclude MRI scanning.
Medications:
* Current and/or past regular use of hormone-containing medications (excluding contraceptives)
* Use of medications such as oral corticosteroids which may have immunosuppressive effects.
* Current use of non-steroid anti-inflammatory drugs that is deemed by the investigators to potentially confound the results of the study (e.g. \> 3 days/week)
* Current and/or past regular use of immune modifying drugs that target specific immune responses such as TNF antagonists
* Current use of analgesics such as opioids or history of addiction to opioids or other analgesics
* Current and/or past regular use of cardiovascular medications, including antihypertensive, antiarrhythmic, anti-anginal, and anticoagulant drugs (does not apply where medications are taken for different purpose e.g. anti-hypertensives for migraine).
* Chronic use of antibiotics such as isotretinoin or minocycline because of their potential effects on the microbiome and immune function.
* Evidence of recreational drug use from urine test.
* Lifetime use of methamphetamine
* Inclusion of individuals reporting other types of medications or supplements not listed or considered thus far will be at the discretion of the PI based on their potential to affect immune function, the microbiome, brain function or brain blood flow.
Health Factors:
* BMI \> 35 because of the effects of obesity on pro-inflammatory cytokine activity
* Clinically significant abnormalities on screening laboratory tests
* Abnormal EKG
* In addition, participants who on arrival to the study, show any of the following symptoms will not be allowed to complete the study:
1. screening supine systolic blood pressure \>140 mmHg or \<100 mmHg
2. screening supine diastolic blood pressure \>90 mmHg or \<60 mmHg
3. 12-lead EKG demonstrating a PR interval \> 0.2 msec QTc \>450 or QRS \>120 msec (Bazett) If the QTc exceeds 450 msec, or QRS exceeds 120 msec, the EKG will be repeated 2 more times and the median value will be used
4. pulse less than 50 beats/minute or greater than 100 beats/minute
5. temperature greater than 99.5 degrees F.
Non-English speaking participants:
* The majority of the assessments proposed for this study have not been translated from English, thus, non-English speaking volunteers will be excluded.
Where it's running
-
Laureate Institute for Brain Research
Tulsa, Oklahoma, United States Recruiting
Study contacts
- Study coordinator: Jonathan Savitz, PhD
- Email: jsavitz@laureateinstitute.org
- Phone: 918 502 5104
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Dupilumab for Major Depressive Disorder
This study tests whether dupilumab can engage immune targets in adults with major depressive disorder to see if it can help with depressive symptoms.
-
Accelerated vs Standard iTBS for Major Depression
This trial tests whether giving more accelerated iTBS sessions is better tolerated and more effective than the standard schedule for adults with major depressive disorder.
-
Psilocybin with Structured Integrated Reframing Therapy for trauma-related MDD and PTSD
This trial tests whether psilocybin therapy, alone or with Structured Integrated Reframing Therapy (SIRT), helps people with trauma-related major depressive disorder who are already on a stable antidepressant.
-
Magnesium Bisglycinate Added to Your Depression Treatment
This study tests whether adding magnesium bisglycinate to your current antidepressant can help reduce depressive symptoms and improve sleep and daily functioning for adults with major depressive disorder.
-
Motif XCS System for treatment-resistant depression
This study tests whether the Motif XCS System is safe and tolerable and might help people with treatment-resistant major depressive disorder.
-
A Phase 3 test of DT120 for major depressive disorder
DT120 is tested against placebo in adults with major depressive disorder to see if it can help reduce depressive symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.